WO1997038701A1 - Composition and method for the treatment of premenstrual syndrome - Google Patents
Composition and method for the treatment of premenstrual syndrome Download PDFInfo
- Publication number
- WO1997038701A1 WO1997038701A1 PCT/CA1996/000229 CA9600229W WO9738701A1 WO 1997038701 A1 WO1997038701 A1 WO 1997038701A1 CA 9600229 W CA9600229 W CA 9600229W WO 9738701 A1 WO9738701 A1 WO 9738701A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium
- magnesium
- present
- diuretic
- analgesic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Definitions
- the present invention relates to therapeutic compositions and methods and in particular compositions and methods for treatment of an individual exhibiting symptoms of premenstrual syndrome.
- PMS premenstrual syndrome
- PMS The specific etiology of PMS remains unknown, although many theories have been proposed. These include: hormonal imbalances, hormonal deficiencies, vitamin deficiencies, disturbances of the autonomic nervous system, salt and water imbalances, altered endogenous opiates and psychosomatic dysfunction.
- M.Ferin, R.Jewelewicz and M.Warren The Menstrual Cvcle; Physiology. Reproductive Disorders, and Infertility, pp. 198-204 (1993).
- PMS is multifactorial and probably also involves changes in neurohormones and neurotransmitters, which are not easily documented in humans. Numerous attempts have been made to develop an effective treatment for the symptoms of PMS. Dietary modification including reduction of salt, alcohol, and beverages containing caffeine have been suggested. Pharmacologic intervention is commonly used, especially progesterone therapy and hypothalamic-pituitary-ovarian axis suppressors.
- Nonprescription pharmacologic compositions have also been made available. Most provide aspirin or acetaminophen as an analgesic for diminishing menstrual pain. Calcium has also been found to be an effective treatment, especially in regard to premenstrual pain and water retention. S.Thys-Jacobs,
- Another object of the present invention is to provide a composition for the treatment of PMS symptoms that achieves enhanced compliance from the patient and therefore better results because each of the active ingredients required to treat the various symptoms are provided within a single formulation.
- the present invention provides a method for treating premenstrual syndrome comprising administering an effective amount of calcium, magnesium, an analgesic and a diuretic so that the symptoms of premenstrual syndrome are reduced.
- the present invention is also directed to a composition for the relief of pain and discomfort associated with premenstrual syndrome comprising and effective amount of calcium, magnesium, an analgesic and a diuretic.
- composition according to the present invention is a formulation including at least four separate active ingredients: (1) magnesium; (2) calcium; (3) an analgesic; and (4) a diuretic.
- Aspirin acetylsalicylic acid
- acetaminophen acetaminophen
- ibuprofen are each effective analgesics within the scope of the present invention.
- the analgesic functions to relieve the symptoms of abdominal cramps, back pain and pain from swollen and tender breasts as well a ⁇ headache pain.
- the analgesic acetaminophen is administered in a dose of about 500 mg. four times a day for a total of about 2000 mg/day.
- the diuretic is provided to relieve symptoms related to water retention such a ⁇ excessive water weight, bloating, swelling, painful breasts, cramps and tension.
- the preferred diuretic within the scope of the present invention is pamabrom, a theophylline derivative.
- ammonium chloride, an acid-forming salt may be used.
- caffeine is not a preferred diuretic since it tends to extend the symptoms of PMS rather than provide relief.
- the diuretic is administered in a dose of about 25 mg four times a day for a total of about 100 mg/day.
- Elemental magnesium (Mg 2+ ) is provided for relief of "negative affect" i.e. premenstrual mood fluctuations.
- Mg cation supplementation must be sufficient to increase the cation content in both the lymphocytes and polymorphonuclear cells. This generally means a dosage higher than the recommended dietary allowances set by the National Academy of Sciences but low enough to avoid the risk of overload.
- Applicant has determined that the magnesium cation be administered in a dose of about 100 mg of magnesium four times a day for a total of about 400 mg/day.
- Preferred sources of magnesium ion for oral ingestion include magnesium glucoheptonate, magnesium pyrrolidone carboxylic acid, magnesium gluconate, magnesium pyroglutamate and magnesium sulfate.
- Elemental calcium provides relief for both the physical and behavioral symptoms of PMS. Behavioral symptoms are generally characterized a ⁇ "negative affect”. Within the meaning of the present invention these include depression, violent tendencies, crying, mood swings, irritability and nervousness. Physical symptoms treated by the calcium therapy according to the present invention include headache, back pain, water retention, abdominal bloating and cramps, breast tenderness and fatigue. Applicant has determined that the calcium be administered in a dose of about 300 mg four times a day for a total of about 1200 mg/day.
- the source of calcium for the formulation according to the present invention is in the form of calcium carbonate, calcium chloride, calcium glucoheptonate, calcium gluconate, calcium gluconogalactogluconate, calcium gluceptate, calcium lactate, calcium glubionate, calcium phosphate dibasic anhydrous, calcium phosphate dibasic dihydrate and calcium phosphate tribasic.
- Both the magnesium and calcium within the scope of the present invention must be in a form to allow the ions to be readily adsorbed by the body.
- the above described calcium and magnesium compounds allow such absorption into the body.
- Antacid agents are to be avoided since magnesium or calcium cations are less readily adsorbed from such compounds.
- Example 1 The specific formulation set forth above produces optimal therapeutic results within the permissible deviation indicated. However, certain individual ingredients may vary in amount and still produce satisfactory results. The following specific examples are representative of the composition according to the present invention: Example 1
- composition according to the present invention is effective in treating all the major symptoms of PMS by provide a broad therapeutic spectrum.
- Each of the active ingredient ⁇ will address certain of the PMS symptoms.
- the overlapping nature of the active ingredient ⁇ within the method and composition of the present invention enhances the effectiveness of treatment while at the ⁇ ame time compensating for deficiencies of a particular ingredient.
- the magnesium will provide the greatest relief for water retention and negative affect. By itself, it has virtually no effect on the remaining symptoms.
- calcium provides a broad-based treatment for every one of the symptoms; "negative affect” and water retention are only somewhat improved.
- the analgesic component fills the remaining gaps in treatment, especially in regard to pain, headache and soreness while the diuretic targets water retention and its related symptoms.
- a broad-based , therapeutic spectrum is achieved having improvements over the prior art methods and formulations.
- Applicant believes that the present combination of active ingredients and method steps, especially those designed to address the same symptoms, produce a synergistic improvement in therapy over the individual ingredients alone. Since the applicant has selected active ingredients designed to address each of the various symptoms through different mechanisms of action, their cumulative effect produces improved treatment.
- the formulation of the present invention may be incorporated within any suitable carrier known in the art, for example sucrose or dextrose. It may be in tablet or capsule form, in chewable or effervescent tablet or in liquid form. Further, the formulation may be prepared as a sustained release capsule or tablet with the concentration of the active ingredients being that for the total daily dosage. While this invention has been described as having a preferred designs, it is understood that it is capable of further modifi ⁇ ations, uses and/or adaptations of the invention following in general the principle of the invention and including such departures from the present disclosure as come within the known or customary practice in the art to which the invention pertains and as may be applied to the central features hereinbefore set forth, and fall within the scope of the invention and of the limits of the appended claims.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A composition for the treatment of premenstrual syndrome comprising an effective amount of calcium, magnesium, an analgesic and a diuretic sufficient to reduce the symptons of premenstrual syndrome.
Description
COMPOSITION AND METHOD FOR THE TREATMENT OF PREMENSTRUAL SYNDROME
FIELD OF THE INVENTION The present invention relates to therapeutic compositions and methods and in particular compositions and methods for treatment of an individual exhibiting symptoms of premenstrual syndrome.
BACKOROϋND OF THE INVENTION
The premenstrual syndrome (PMS) is a cyclic disorder occurring during the late luteal phase of the menstrual cycle and ending once menstrual flow returns. The condition was first described over sixty years ago as "premenstrual tension syndrome". The most common symptoms of PMS include bloating, abdominal discomfort, change in appetite, breast tenderness, and headache. Behavioral changes include fatigue, depression, anxiety, irritability, anger, confusion, and social withdrawal. The symptoms of PMS are often so severe and widespread that the American Pβychitric Association has formally
identified the diagnostic criteria for PMS in Diagnostic and Statistical Manual of Mental Disorders.
The specific etiology of PMS remains unknown, although many theories have been proposed. These include: hormonal imbalances, hormonal deficiencies, vitamin deficiencies, disturbances of the autonomic nervous system, salt and water imbalances, altered endogenous opiates and psychosomatic dysfunction. Up to now, investigative studies of etiology have been inconclusive and sometimes conflicting. M.Ferin, R.Jewelewicz and M.Warren, The Menstrual Cvcle; Physiology. Reproductive Disorders, and Infertility, pp. 198-204 (1993). Most likely, PMS is multifactorial and probably also involves changes in neurohormones and neurotransmitters, which are not easily documented in humans. Numerous attempts have been made to develop an effective treatment for the symptoms of PMS. Dietary modification including reduction of salt, alcohol, and beverages containing caffeine have been suggested. Pharmacologic intervention is commonly used, especially progesterone therapy and hypothalamic-pituitary-ovarian axis suppressors.
Nonprescription pharmacologic compositions have also been made available. Most provide aspirin or acetaminophen as an analgesic for diminishing menstrual pain. Calcium has also been found to be an effective treatment, especially in regard to premenstrual pain and water retention. S.Thys-Jacobs,
S.Ceccarelli, A.Bierman, H.Weisman, M.A.Cohen and J.Alvir, Calcium-supplementation in premenstrual Bvndrome; A randomized crossover trial. J.Gen.Int.Med. 4slB3-189, (1989) . Magnesium supplementation has been documented to relieve certain other symptoms of PMS including pain, negative affect and arousal i.e. mood fluctuations although other symptoms were unaffected.
F.Fancchinetti, P.Borella, G.Sanceβ, L.Fioroni, R.Nappi and A.R.Genazzani, Oral Magnesium Successfully Relieves Premenstrual Mood Changes. Obstetrics & Gynecology 78:177-181,(1991).
None of the prior art nonprescription compositions have been found to be completely effective. Although they alleviate certain symptoms of PMS, other symptoms remain untreated or show little or no improvement. Further, at least some prior art compositions are known to contain ingredients that cause undesirable side effects. For example, U.S. 5,001,688 (Calam et al.) contains both ethyl alcohol and an antihistamine which can cause drowsiness. Further, none of the active ingredients reduce negative effect, fatigue or bloating. Midol, a commercially available nonprescription composition has contained aspirin along with caffeine and an antispasmodic ingredient. Recent investigations have indicated that consumption of caffeine containing beverages is strongly related to the prevalence and severity of PMS and should therefore be avoided. A.Mackay- Rossignol and H.Bonnlander♦Caffeine- Containing Beverages. Total Fluid Consumption, and Premenstrual syndrome. Am.J.Pub.Health, pg.1106 (1990).
Thus, a patient is often left with no other choice than to simultaneously take different compositions in an attempt to relieve all of the various symptoms while at the same time try to avoid those known to produce side effects. For obvious reasons such self-medication is undesirable. Even the relatively benign ingredients found in nonprescription drugs present the potential for an overdose. Further, interaction between active ingredients found in different compositions can actually reduce the overall effectiveness of treatment, especially if the active ingredients operate by a similar mechanism.
Since PMS encompasses a broad spectrum of
symptomatology, physicians are faced with a variety of options when deciding on a safe program of treatment. A need has therefore arisen for a single nonprescription composition that will provide a broad therapeutic spectrum while exhibiting greater overall activity.
Against this background the present invention was developed.
0BJECT8 AND BUMMfLRY OF THE INVENTION It is an object of the present invention to provide a nonprescription pharmaceutical composition for the relief of the broad spectrum of symptoms associated with premenstrual syndrome (PMS) .
It is another object of the present invention to provide a nonprescription pharmaceutical composition for the relief of PMS within a single formulation thereby eliminating the need for ingesting multiple medications.
Another object of the present invention is to provide a composition for the treatment of PMS symptoms that achieves enhanced compliance from the patient and therefore better results because each of the active ingredients required to treat the various symptoms are provided within a single formulation.
It is yet another object of the present invention to provide a nonprescription composition for the treatment of PMS containing two mineral replacements along with an analgesic and a non-caffeine diuretic to provide combination therapy having a broad therapeutic spectrum.
It is another object of the present invention to provide a single nonprescription pharmaceutical composition for the treatment of PMS containing multiple active ingredients which in combination have an overall synergistic effect providing
improved therapeutic activity.
It is still another object of the present invention to provide a method for the treatment of premenstrual syndrome through the administration of two minerals, an analgesic and a diuretic.
In summary, the present invention provides a method for treating premenstrual syndrome comprising administering an effective amount of calcium, magnesium, an analgesic and a diuretic so that the symptoms of premenstrual syndrome are reduced.
The present invention is also directed to a composition for the relief of pain and discomfort associated with premenstrual syndrome comprising and effective amount of calcium, magnesium, an analgesic and a diuretic. These and other objects of the present invention will become apparent from the following detailed description.
DETAILED DESCRIPTION OF THE INVENTION The composition according to the present invention is a formulation including at least four separate active ingredients: (1) magnesium; (2) calcium; (3) an analgesic; and (4) a diuretic. Aspirin (acetylsalicylic acid) , acetaminophen and ibuprofen are each effective analgesics within the scope of the present invention. The analgesic functions to relieve the symptoms of abdominal cramps, back pain and pain from swollen and tender breasts as well aβ headache pain. In a preferred embodiment, the analgesic acetaminophen is administered in a dose of about 500 mg. four times a day for a total of about 2000 mg/day.
The diuretic is provided to relieve symptoms related to water retention such aβ excessive water weight, bloating,
swelling, painful breasts, cramps and tension. The preferred diuretic within the scope of the present invention is pamabrom, a theophylline derivative. In addition, ammonium chloride, an acid-forming salt may be used. As noted above, caffeine is not a preferred diuretic since it tends to extend the symptoms of PMS rather than provide relief. In the preferred embodiment, the diuretic is administered in a dose of about 25 mg four times a day for a total of about 100 mg/day.
Elemental magnesium (Mg2+) is provided for relief of "negative affect" i.e. premenstrual mood fluctuations. Mg cation supplementation must be sufficient to increase the cation content in both the lymphocytes and polymorphonuclear cells. This generally means a dosage higher than the recommended dietary allowances set by the National Academy of Sciences but low enough to avoid the risk of overload. Applicant has determined that the magnesium cation be administered in a dose of about 100 mg of magnesium four times a day for a total of about 400 mg/day. Preferred sources of magnesium ion for oral ingestion include magnesium glucoheptonate, magnesium pyrrolidone carboxylic acid, magnesium gluconate, magnesium pyroglutamate and magnesium sulfate.
Elemental calcium (Ca2*) provides relief for both the physical and behavioral symptoms of PMS. Behavioral symptoms are generally characterized aβ "negative affect". Within the meaning of the present invention these include depression, violent tendencies, crying, mood swings, irritability and nervousness. Physical symptoms treated by the calcium therapy according to the present invention include headache, back pain, water retention, abdominal bloating and cramps, breast tenderness and fatigue. Applicant has determined that the calcium be administered in a dose of about 300 mg four times a day for a
total of about 1200 mg/day. In the preferred embodiment, the source of calcium for the formulation according to the present invention is in the form of calcium carbonate, calcium chloride, calcium glucoheptonate, calcium gluconate, calcium gluconogalactogluconate, calcium gluceptate, calcium lactate, calcium glubionate, calcium phosphate dibasic anhydrous, calcium phosphate dibasic dihydrate and calcium phosphate tribasic.
Both the magnesium and calcium within the scope of the present invention must be in a form to allow the ions to be readily adsorbed by the body. The above described calcium and magnesium compounds allow such absorption into the body. Antacid agents are to be avoided since magnesium or calcium cations are less readily adsorbed from such compounds.
A formulation according to the present invention may be summarized in Table 1 set forth below:
TABLE I
The specific formulation set forth above produces optimal therapeutic results within the permissible deviation indicated. However, certain individual ingredients may vary in amount and still produce satisfactory results. The following specific examples are representative of the composition according to the present invention:
Example 1
Example 2
Example 3
Example 4
Example 6 Liquid Formulation
The composition according to the present invention is effective in treating all the major symptoms of PMS by provide a broad therapeutic spectrum. Each of the active ingredientβ will address certain of the PMS symptoms. The overlapping nature of the active ingredientβ within the method and composition of the present invention enhances the effectiveness of treatment while at the βame
time compensating for deficiencies of a particular ingredient.
For example, the magnesium will provide the greatest relief for water retention and negative affect. By itself, it has virtually no effect on the remaining symptoms. Conversely, although calcium provides a broad-based treatment for every one of the symptoms; "negative affect" and water retention are only somewhat improved. However, by combining calcium and magnesium according to the present method and formulation, symptoms such as cramping and back pain are fully addressed while an overall synergistic improvement in treatment is achieved with respect to negative affect. The analgesic component fills the remaining gaps in treatment, especially in regard to pain, headache and soreness while the diuretic targets water retention and its related symptoms. Thus, a broad-based, therapeutic spectrum is achieved having improvements over the prior art methods and formulations.
Applicant believes that the present combination of active ingredients and method steps, especially those designed to address the same symptoms, produce a synergistic improvement in therapy over the individual ingredients alone. Since the applicant has selected active ingredients designed to address each of the various symptoms through different mechanisms of action, their cumulative effect produces improved treatment.
The formulation of the present invention may be incorporated within any suitable carrier known in the art, for example sucrose or dextrose. It may be in tablet or capsule form, in chewable or effervescent tablet or in liquid form. Further, the formulation may be prepared as a sustained release capsule or tablet with the concentration of the active ingredients being that for the total daily dosage. While this invention has been described as having a preferred designs, it is understood that it is capable of further
modifiσations, uses and/or adaptations of the invention following in general the principle of the invention and including such departures from the present disclosure as come within the known or customary practice in the art to which the invention pertains and as may be applied to the central features hereinbefore set forth, and fall within the scope of the invention and of the limits of the appended claims.
Claims
1. A therapeutic composition for the treatment of premenstrual syndrome comprising an effective amount of: a) calcium; b) magnesium; c) an analgesic; and d) a diuretic.
2. A therapeutic composition as in claim 1 and wherein: a) said calcium selected from the group consisting of calcium carbonate, calcium chloride, calcium glucoheptonate, calcium gluconate, calcium gluconogalactogluconate, calcium gluσeptate, calcium lactate, calcium glubionate, calcium phosphate dibasic anhydrous, calcium phosphate dibasic dihydrate and calcium phosphate tribasic.
3. A therapeutic composition as in claim 1 and wherein: a) said magnesium selected from group consisting of magnesium glucoheptonate, magnesium pyrrolidone carboxylic acid, magnesium gluconate, magnesium pyroglutamate and magnesium sulfate.
4. A therapeutic composition as in claim 1 and wherein: a) said analgesic selected from the group consisting of acetylsalicylic acid, acetaminophen and ibuprofen.
5. A therapeutic composition as in claim 1 and wherein: a) said diuretic selected from the group consisting of pamabrom and ammonium chloride.
6. A therapeutic composition as in claim 1 and wherein: a) said analgesic is present from about 40 to about 60 percent by weight of the composition; b) said diuretic is present from about 3.2 to about 4.8 percent by weight of the composition; c) said calcium is present from about 27.2 to about
40.8 percent by weight of the composition;and d) said magnesium is present from about 9.2 to about 13.8 percent by weight of the composition.
7. A method for the relief of premenstrual syndrome comprising the step of: a) administering an effective amount of calcium, magnesium, an analgesic and a diuretic so that the symptoms of premenstrual syndrome are reduced.
8. The method of claim 7 and wherein: a) the effective amount of calcium is about 1200 mg per day; b) the effective amount of magnesium is about 400 mg. per day; c) the effective amount of analgesic is about 2000 mg. per day; and d) the effective amount of diuretic is about 100 mg. per day.
9. The method of claim 7 in which each of the recited ingredients is administered orally.
10. The method of claim 9 and wherein: a) the calcium is administered in the form of a compound selected from the group consisting of calcium carbonate, calcium chloride, calcium glucoheptonate, calcium gluconate, calcium gluconogalactogluconate, calcium gluceptate, calcium lactate, calcium glubionate, calcium phosphate dibasic anhydrous, calcium phosphate dibasic dihydrate and calcium phosphate tribasic.
11. The method of claim 9 and wherein: a) The magnesium is administered in the form of a compound selected from the group consisting of magnesium glucoheptonate, magnesium pyrrolidone carboxylic acid, magnesium gluconate, magnesium pyroglutamate and magnesium sulfate.
12. The method of claim 9 and wherein: a) the analgesic is administered in the form of a compound selected from the group consisting of acetylsalicylic acid, acetaminophen and ibuprofen.
13. The method of claim 9 and wherein: a) the diuretic is administered in the form of a compound selected from the group consisting of pamabrom and ammonium chloride.
14. A therapeutic composition according to claim 1 wherein: a) said analgesic is acetaminophen present from about 40 to about 60 parts by weight; b) said diuretic is pamabrom present from about 2.7 to 5.3 parts by weight; c) said calcium is present as calcium carbonate from about 27.2 to about 40.8 parts by weight; and d) said magnesium is present as magnesium gluconate from about 9.2 to about 13.8 parts by weight.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU52655/96A AU5265596A (en) | 1996-04-12 | 1996-04-12 | Composition and method for the treatment of premenstrual syndrome |
| PCT/CA1996/000229 WO1997038701A1 (en) | 1996-04-12 | 1996-04-12 | Composition and method for the treatment of premenstrual syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA1996/000229 WO1997038701A1 (en) | 1996-04-12 | 1996-04-12 | Composition and method for the treatment of premenstrual syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997038701A1 true WO1997038701A1 (en) | 1997-10-23 |
Family
ID=4173147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA1996/000229 WO1997038701A1 (en) | 1996-04-12 | 1996-04-12 | Composition and method for the treatment of premenstrual syndrome |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU5265596A (en) |
| WO (1) | WO1997038701A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841551B2 (en) * | 2000-01-18 | 2005-01-11 | Hoffmann-La Roche Inc. | Brain, spinal, and nerve injury treatment |
| EP3127546A1 (en) * | 2015-08-06 | 2017-02-08 | Kenneth Davin Fine | Reduction of oxalate absorption in individuals |
| WO2018057737A1 (en) * | 2016-09-22 | 2018-03-29 | Cash Alan B | Method to alleviate the symptoms of pms |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0081823A1 (en) * | 1981-12-10 | 1983-06-22 | WHITBY RESEARCH, Inc. | Composition for reducing menstrual pain |
| EP0246177A2 (en) * | 1986-05-14 | 1987-11-19 | George H. Clark | A beverage and method for making a beverage for the nutritional supplementation of calcium in humans |
| US4888343A (en) * | 1986-09-15 | 1989-12-19 | Bristol-Myers Company | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process |
| US4946679A (en) * | 1988-07-25 | 1990-08-07 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome |
| CA2150417A1 (en) * | 1994-10-14 | 1996-04-15 | Simon W. Rabkin | Composition and method for the treatment of premenstrual syndrome |
-
1996
- 1996-04-12 WO PCT/CA1996/000229 patent/WO1997038701A1/en active Application Filing
- 1996-04-12 AU AU52655/96A patent/AU5265596A/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0081823A1 (en) * | 1981-12-10 | 1983-06-22 | WHITBY RESEARCH, Inc. | Composition for reducing menstrual pain |
| EP0246177A2 (en) * | 1986-05-14 | 1987-11-19 | George H. Clark | A beverage and method for making a beverage for the nutritional supplementation of calcium in humans |
| US4888343A (en) * | 1986-09-15 | 1989-12-19 | Bristol-Myers Company | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process |
| US4946679A (en) * | 1988-07-25 | 1990-08-07 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome |
| CA2150417A1 (en) * | 1994-10-14 | 1996-04-15 | Simon W. Rabkin | Composition and method for the treatment of premenstrual syndrome |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841551B2 (en) * | 2000-01-18 | 2005-01-11 | Hoffmann-La Roche Inc. | Brain, spinal, and nerve injury treatment |
| US9186404B2 (en) | 2000-01-18 | 2015-11-17 | Eustralis Pharmaceuticals Limited | Brain, spinal and nerve injury treatment |
| US10201568B2 (en) | 2000-01-18 | 2019-02-12 | Eustralis Pharmaceuticals Limited | Brain, spinal, and nerve injury treatment |
| EP3127546A1 (en) * | 2015-08-06 | 2017-02-08 | Kenneth Davin Fine | Reduction of oxalate absorption in individuals |
| WO2018057737A1 (en) * | 2016-09-22 | 2018-03-29 | Cash Alan B | Method to alleviate the symptoms of pms |
| JP2019529559A (en) * | 2016-09-22 | 2019-10-17 | アラン ビー． キャッシュ， | How to reduce symptoms of PMS |
| US11071722B2 (en) | 2016-09-22 | 2021-07-27 | Alan B. Cash | Method to alleviate the symptoms of PMS |
| JP7291079B2 (en) | 2016-09-22 | 2023-06-14 | アラン ビー． キャッシュ， | How to reduce symptoms of PMS |
| AU2017330348B2 (en) * | 2016-09-22 | 2023-09-07 | Alan B. Cash | Method to alleviate the symptoms of PMS |
| US11865092B2 (en) | 2016-09-22 | 2024-01-09 | Alan B. Cash | Method to alleviate the symptoms of PMS |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5265596A (en) | 1997-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5612061A (en) | Composition and method for the treatment of premenstrual syndrome | |
| US6500450B1 (en) | Composition for treating migraine headaches | |
| Lione | The prophylactic reduction of aluminium intake | |
| Schachter et al. | Treatment of oligospermia with the amino acid arginine | |
| US4221784A (en) | Process and composition for treating disorders by administering lecithin | |
| US4387093A (en) | Arthritis treatment | |
| CA2735834C (en) | Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis | |
| EP1784177B1 (en) | Formulation for l-tryptophane comprising carbidopa/benserazide | |
| US8129430B2 (en) | Method of reducing phosphate nephropathy in a mammal | |
| US20030125303A1 (en) | Transdermal formulation for repair and maintenance of connective tissue | |
| WO1997038701A1 (en) | Composition and method for the treatment of premenstrual syndrome | |
| DE3500670A1 (en) | MEDICINAL PRODUCTS CONTAINING DIPHOSPHONATES | |
| US4650668A (en) | Composition for relieving toothache pain and other forms of intense pain | |
| DE3936319C2 (en) | ||
| DE102022103658A1 (en) | Drug composition containing L-tryptophan (L-Try) and L-5-hydroxytryptophan (5-HTP) and a peripheral degradation inhibitor | |
| US4575506A (en) | Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics | |
| WO2003022292A1 (en) | Oral pharmaceutical formulation containing active carbon and use of the same | |
| GB2595077A (en) | Combination of gaboxadol and lithium for the treatment of psychiatric disorders | |
| Rose et al. | Effect of dihydrotachysterol in treatment of parathyroid deficiency | |
| US3055805A (en) | Process of treating acidosis with t.h.a.m. | |
| JPH061721A (en) | Pain treating agent and pain mitigating activity potentiator | |
| CN1180789C (en) | Compound medicine for migraine | |
| US20200254009A1 (en) | Potassium enriched topical formulations for pain relief and sleep aid | |
| Fazio et al. | Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor | |
| JP2024061731A (en) | Dietary supplement for use in the prevention and treatment of migraine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP MX |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97536595 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |